Skip to main content

Table 4 Studies on LPD for pancreatic cancer

From: Expanding laparoscopic pancreaticoduodenectomy to pancreatic-head and periampullary malignancy: major findings based on systematic review and meta-analysis

  Croome Hakeem Chen Song Dokmak Stauffer Kantor Conrad Palanivelu Khaled Meng
Age (years) 66.6 ± 9.6 67.0 ± 10.2 68.1 ± 7 69.9(40.6–84.8) 65.9 ± 10.7 68(45–83) 57.8 ± 2.0 65(35–78) 60.0 ± 9.1
Sex (M/F) 57/51 8/4 32/26 26/14 18/14 8/7 32/26
BMI 27.4 ± 5.4 25.8 ± 3.7 25.9(17.7–49.6) 23.9(14.9–34.1) 24.9 ± 0.7 23.4(18–26) 22.3 ± 3.0
Tumor size (cm) 3.3 ± 1.0 2.0 ± 1.0 3.0 ± 0.9 2.8 ± 0.6 2.4(1.5–4) 2.5(0.3–10.0) 2.5 (0.3–8.0) 3.3 ± 0.7 2.0(0.7–8.0) 1.9(1.5–2.6)
Retrieved LNs 21.4 ± 8.1 20.7 ± 6.3 18.1 ± 6.6 15 ± 10 20(8–59) 27(9–70) 18.1 ± 9.5 18(6–53) 18.9 ± 1.0 18(14–19) 16(15–18)
R0 rate 77.8% 75.0% 94.7% 72.7% 60% 84.5% 79.1% 87.5% 96.9% 86.7% 100%
Operative time (min) 379.4 ± 93.5 518(313–761) 359 ± 14 470(280–660) 475(420–546)
Blood loss (mL) 492.4 ± 519.3 250(50–8500) 250 ± 22 300(50–600) 200(100–325)
POPF 16.7% 20% 11.8% 30% 15.6% 20.0% 55.2%
Significant POPF 11% 7.8% 6.3% 20.0% 13.8%
Morbidity 5.6% CD>2 58.3% 53% 53.4% 95% 25.0% 40.0% 15.5% CD>2
Hospital stay (days) 6 (4–118) 14.9 ± 6.6 15(6–53) 6(4–68) 10.2 ± 8.5 24.5(9–311) 7(5–52) 9.0(7–20) 14.0(11.0–17.3)
Readmission 22.4% 90d 6.8% 30d 6.3% 90d
Mortality 0.9% 30d 0% 30d 0% 30d 0% 90d 3.4% 90d 6.9% 90d 5% 90d 3.1% 90d 0% 30d 1.7% 30d
Survival MS: 25.3 m 1,3,5y-DFS:100,92,83%; 1,3,5y-OS:100,92,75%. 5y-OS:
53.6%
1,2,3,4,5y-OS:
66.5,43.3,43.3%,
38.5,32.1%
MS: 20.7 m MS: 35.5 m;
1,3,5y-DFS: 62.3, 37.9, 25.7%; 1,3,5y-OS: 80.5, 49.2, 39.7%
1,3,5y-OS: 100, 80, 67% MS: 45 m
  1. OS overall survival rate, MS median survival time, m month